Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Cannabix Technologies Inc C.BLO

Alternate Symbol(s):  BLOZF

Cannabix Technologies Inc. is a Canada-based developer of marijuana and alcohol breathalyzer technologies for law enforcement, workplaces and laboratories. The Company is working to develop delta-9 tetrahydrocannabinol (THC) and alcohol screening devices. Delta-9 THC is the psychoactive component of marijuana. Breath testing for delta-9 THC would allow employers and law enforcement to identify recent marijuana use. It develops contactless breath alcohol detection devices. Its technologies include THC Breathalyzer System, Breath Logix Alcohol Breathalyzer and Breath Logix Vehicle. THC Breathalyzer System includes Cannabix Mass Spectrum (MS) Breath Sampler (MSBS) and Cannabix Breath Collection Unit (BCU). The Breath Logix (BR-LGX) Industrial Series is a fully automated breath alcohol screening system for employee, contractor and visitor access control. The BR-LGX vehicle device could be integrated into various locations in the vehicle cabin. It also develops Cannabix FAIMS device.


CSE:BLO - Post by User

Post by Betteryear2on Aug 17, 2021 8:50am
294 Views
Post# 33715904

Granted U.S. Patent for FAIMS molecular analysis device

Granted U.S. Patent for FAIMS molecular analysis device

VANCOUVER, British Columbia, Aug. 17, 2021 (GLOBE NEWSWIRE) -- Cannabix Technologies Inc. (CSE: BLO) (OTC PINK: BLOZF) (the “Company” or “Cannabix”) developer of the Cannabix Marijuana Breathalyzer devices for law enforcement and the workplace, is pleased to report that the United States Patent and Trademark Office (USPTO) has granted patent No. 17/019728 entitled, “Apparatus and Methods for Detection of Molecules” to the Company. This patent is centered on innovations made by Cannabix with its FAIMS (field asymmetric waveform ion mobility spectrometry) based marijuana breathalyzer technology. This patent is the culmination of research and development work conducted by Cannabix scientists and engineers in the areas of ion mobility spectrometry, non-volatile molecule sampling and fluid dynamics. These developments provide utility in several areas related to detection of target molecules in breath.

The Company is developing a FAIMS based drug screening device that would be used by law enforcement, laboratories and other end users to detect cannabis in exhaled breath. Cannabix is using its FAIMS technology to detect 9-tetrahydrocannabinol (“THC”), a non-volatile compound, in breath. The Cannabix FAIMS marijuana breathalyzer device uses ion mobility filtering techniques related to mass spectrometry – the gold standard analytical technique for molecular detection. The Cannabix device has been designed and built in a series of modules that together allow for sample intake, ionization, filtering and detection at atmospheric pressure. In addition, the device has the ability to couple directly to a mass spectrometer for validation with gold standard techniques. In conjunction with the accomplishments described in the granted patent, engineers have been improving efficiencies in the electronics, sample intake and portability.

The Company has been steadily growing its intellectual property (IP) portfolio over recent months. In June, the Company was granted patent No. 2887841 entitled, “Cannabis Drug Detection Device” from the Canadian Intellectual Property Office. In January, the USPTO granted a granted patent No. 14/689434 entitled, “Cannabis Drug Detection Device” to the Company. This newly granted patent from the USPTO for FAIMS and the detection of molecules is a welcome addition to the Company’s IP development efforts.

 
<< Previous
Bullboard Posts
Next >>